Solitomab-treated animals had decreased tumor burden over time (Fig. 4 C) and exhibited a significant increase in ZipGFP-Casp3–labeled apoptotic cells starting at 24 h after therapy compared with control EpCAM antibody–treated fish (P < 0.01, Student’s test; Fig. 4, B and D). Here, EPCAM is linked to neoplasm.